All articles by Srivani Venna

1. Genome & Company, Merck and Pfizer sign clinical trial agreement

   Genome & Company, Merck and Pfizer have signed a clinical trial collaboration and supply agreement to evaluate GEN-001 therapy in…
   Read More…

   14 Jan
2. Akero to expand ongoing Phase IIa trial of AKR-001 for NASH

   Akero Therapeutics is set to expand the ongoing Phase IIa BALANCED study of Fc-FGF21 fusion protein AKR-001 to include an…
   Read More…

   14 Jan
3. Compass Pathways reports positive data from psilocybin trial

   Mental healthcare company Compass Pathways has reported positive results from a Phase I trial evaluating the safety of COMP360 (psilocybin)…
   Read More…

   13 Dec
4. Lilly launches trial to examine selpercatinib in NSCLC patients

   Eli Lilly and Company has launched the LIBRETTO-431 Phase III clinical trial (NCT04194944) to examine selpercatinib (LOXO-292) for treatment-naïve RET…
   Read More…

   12 Dec
5. AstraZeneca and Daiichi Sankyo report positive cancer drug trial data

   AstraZeneca and Daiichi Sankyo have reported that experimental breast cancer drug trastuzumab deruxtecan (DS-8201) halted cancer in women who had…
   Read More…

   12 Dec
6. ProQR doses first patient in Aurora trial of retinal disease therapy

   ProQR Therapeutics has dosed the first patient in a Phase I/II Aurora clinical trial to evaluate QR-1123 in patients with…
   Read More…

   12 Dec
7. Sanofi’s trial of sutimlimab meets primary and secondary endpoints

   Sanofi has reported positive results from a pivotal Phase III trial of sutimlimab for the treatment of people with cold…
   Read More…

   11 Dec
8. Amgen reports positive data in multiple myeloma study

   Amgen has reported that the primary analysis of the Phase III CANDOR study of Kyprolis in combination with dexamethasone and…
   Read More…

   11 Dec
9. Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL

   Daiichi Sankyo has dosed the first patient in a Phase II study to evaluate the efficacy and safety of valemetostat…
   Read More…

   11 Dec
10. Abeona to initiate Phase III trial of EB-101 to treat RDEB

    Abeona Therapeutics is ready to initiate its pivotal Phase III clinical trial, VIITAL, to evaluate EB-101 for the treatment of…
    Read More…

    10 Dec